Summary
The colorectal cancer (CRC) market, considering the sales of both branded treatments and generic chemotherapy, is expected to experience a moderate growth between 2015 and 2025. The main drivers of growth will be the expected increased number of diagnosed CRC incidence, and the launch and uptake of premium-priced therapies. Traditionally, the CRC market has been dominated by two therapeutic classes: angiogenesis and EGFR inhibitors. However, the efficacy of these agents is limited by the insurgence of acquired resistance. Further, RAS mutant patients, who are not eligible to EGFR inhibitors, have a lower number of available treatment options and usually receive fewer lines of treatment compared with patients with RAS wild-type disease. The CRC competitive landscape is going to experience a substantial change, following the approval of pipeline agents exploiting novel mechanisms of actions, especially immunotherapy. Some pipeline drug developers have invested heavily in the identification of potential predictive biomarkers; therefore, these novel agents are expected to induce further patient stratification and to add complexity to the CRC treatment algorithm, which will be also reshaped by the discovery of the predictive value of tumor sidedness.
Highlights
Key Questions Answered
- The CRC market is characterized by a number of unmet needs in the current treatments. What are the main unmet needs in this market? Will the pipeline drugs under development fulfil these unmet needs?
- The CRC market leader Avastin will experience competition from bevacizumab biosimilars, after its patent expiration in 2018. What will be the impact of bevacizumab biosimilars on the CRC market?
- Nine late-stage pipeline agents are going to enter the CRC market from 2017 onwards. Will the late-stage drugs make a significant impact on the CRC market? Which of these drugs will have the highest peak sales, and why?
Key Findings
- The main driver of the growth of the CRC market will be the increasing CRC incident cases, which is attributed to the aging population.
- The second strongest driver will be the launch of several efficacious pipeline drugs in the metastatic setting, including immunotherapies that will enter the CRC landscape for the first time, and novel molecular-targeted agents, such as BRAF-targeted therapies.
- To gain approval and obtain reimbursement, it is essential for pipeline drugs to demonstrate higher efficacy, in terms of overall survival (OS), compared with available agents. For this reason, almost all the new agents are expected to be positioned in the second- and third-line settings, in which the standard-of-care hurdle is lower.
- The entrance of these agents in the CRC market will intensify the competition in the second-line metastatic setting onwards, which will be worsen by the launch of bevacizumab biosimilars, starting in 2018.
Scope
- Overview of CRC, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Annualized CRC therapeutics market revenue, cost of therapy, and treatment usage pattern data in 8 patient segments, forecast from 2015 to 2025.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the CRC therapeutics market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global CRC therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
- Develop business strategies by understanding the trends shaping and driving the global CRC therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global CRC therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global CRC therapeutics market from 2015-2025.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Companies Mentioned
AB Science
Amgen
Array BioPharma
AstraZeneca
Bayer
Biocad
Boehringer Ingelheim
Bristol-Myers Squibb
BTG International
Daiichi-Sankyo
Cleveland Biolabs
Eli Lilly
GlaxoSmithKline
Gradalis
Hutchinson Medi Pharma
Immunomedics
Immunovative Therapies
Jiangsu Hengrui
Merck KGaA
Merck & Co.
Merrimack
Mologen
Novartis
PsiOxus therapeutics
Roche/Genentech
Sanofi
Sorrento
Sirtex
Sumitomo Dainippon Pharma
Suzhou Zelgen
Symphogen
Taiho Pharmaceuticals
Takeda
Tracon Pharmaceuticals
'
1 Table of Contents
1 Table of Contents 9
1.1 List of Tables 16
1.2 List of Figures 22
2 Introduction 25
2.1 Catalyst 25
2.2 Related Reports 26
2.3 Upcoming Related Reports 26
3 Disease Overview 27
3.1 Etiology and Pathophysiology 27
3.1.1 Etiology 27
3.1.2 Pathophysiology 28
3.1.3 Biomarkers/ Targets of interest 29
3.2 Clinical Staging 32
3.3 Symptoms 34
3.4 Prognosis 34
3.5 Quality of Life 35
4 Epidemiology 37
4.1 Disease Background 37
4.2 Risk Factors and Comorbidities 37
4.3 Global Trends 39
4.3.1 8MM Incidence Trends 39
4.3.2 8MM, Trends in Five-Year Relative Survival 42
4.4 Forecast Methodology 43
4.4.1 Sources Used Tables 44
4.4.2 Forecast Assumptions and Methods 48
4.4.3 Sources Not Used 56
4.5 Epidemiological Forecast for CRC (2015-2025) 56
4.5.1 Diagnosed Incident Cases of CRC 56
4.5.2 Age-Specific Diagnosed Incident Cases of CRC 58
4.5.3 Sex-Specific Diagnosed Incident Cases of CRC 60
4.5.4 Age-Standardized Diagnosed Incidence of CRC 62
4.5.5 Diagnosed Incident Cases of CRC by Stage at Diagnosis 63
4.5.6 Type of Genetic Mutation among Diagnosed Incident Cases of CRC 64
4.5.7 Five-Year Diagnosed Prevalent Cases of CRC 65
4.6 Discussion 67
4.6.1 Epidemiological Forecast Insight 67
4.6.2 Limitations of the Analysis 69
4.6.3 Strengths of the Analysis 70
5 Disease Management 71
5.1 Diagnosis and Treatment Overview 71
5.1.1 Screening and Diagnosis 71
5.1.2 Treatment Guidelines and Leading Prescribed Drugs 77
5.1.3 Clinical Practice 81
5.2 US 97
5.2.1 Screening and Diagnosis 98
5.2.2 Clinical Practice 100
5.3 France 102
5.3.1 Screening and Diagnosis 103
5.3.2 Clinical Practice 104
5.4 Germany 106
5.4.1 Screening and Diagnosis 107
5.4.2 Clinical Practice 108
5.5 Italy 110
5.5.1 Screening and Diagnosis 111
5.5.2 Clinical Practice 112
5.6 Spain 114
5.6.1 Screening and Diagnosis 115
5.6.2 Clinical Practice 116
5.7 UK 118
5.7.1 Screening and Diagnosis 119
5.7.2 Clinical Practice 120
5.8 Japan 122
5.8.1 Screening and Diagnosis 123
5.8.2 Clinical Practice 124
5.9 China 126
5.9.1 Screening and Diagnosis 128
5.9.2 Clinical Practice 129
6 Competitive Assessment 131
6.1 Overview 131
6.2 Anti-angiogenesis drugs 132
6.2.1 Avastin (Bevacizumab) 134
6.2.2 Zaltrap (Ziv-Aflibercept) 146
6.2.3 Cyramza (Ramucirumab) 152
6.3 EGFR Targeted-therapies 157
6.3.1 Erbitux (Cetuximab) 159
6.3.2 Vectibix (Panitumumab) 168
6.4 Kinase Inhibitors 177
6.4.1 Stivarga (Regorafenib) 177
6.5 Chemotherapy 185
6.5.1 Lonsurf (Trifluridine + Tipiracil) 185
6.5.2 TS-1 (Tegafur + Gimeracil + Oteracil) 194
7 Unmet Need and Opportunity 199
7.1 Overview 199
7.2 Understanding and Overcoming Mechanisms of Resistance to Angionesis and EGFR Inhibitors 201
7.2.1 Unmet Need 201
7.2.2 Gap Analysis 203
7.2.3 Opportunity 204
7.3 Targeted Treatments for BRAF Mutation-Positive Patients 205
7.3.1 Unmet Need 205
7.3.2 Gap Analysis 206
7.3.3 Opportunity 206
7.4 Extending the Use of Immunotherapies to the MSS Population 207
7.4.1 Unmet Need 207
7.4.2 Gap Analysis 208
7.4.3 Opportunity 209
7.5 Effective Neoadjuvant/Adjuvant Therapies for High Risk Resectable Disease 210
7.5.1 Unmet Need 210
7.5.2 Gap Analysis 211
7.5.3 Opportunity 212
7.6 Identification of Positive Predictive Biomarkers 213
7.6.1 Unmet Need 213
7.6.2 Gap Analysis 214
7.6.3 Opportunity 214
7.7 Additional and More Effective Later-Line Therapies for Chemotherapy-Resistant Patients 215
7.7.1 Unmet Need 215
7.7.2 Gap Analysis 216
7.7.3 Opportunity 217
8 Pipeline Assessment 218
8.1 Overview 218
8.2 Promising Drugs in Clinical Development 220
8.3 Immunotherapies 221
8.3.1 Lefitolimod (MGN-1703) 222
8.3.2 Keytruda (pembrolizumab) 229
8.3.3 Tecentriq (atezolizumab) 237
8.4 Molecular-Targeted Agents 245
8.4.1 Encorafenib (LGX-818) + Binimetinib (MEK-162) 245
8.4.2 Napabucasin (BBI-608) 254
8.4.3 Vargatef (Nintedanib) 261
8.4.4 Masitinib (AB-1010) 266
8.4.5 Fruquintinib (HMPL-013) 271
8.4.6 Famitinib (SHR-1020) 277
8.4.7 Donafenib (CM-4307) 282
8.5 Promising Approaches in Early Stage Development 285
8.5.1 Strategies to Overcome VEGF-Resistance 285
8.5.2 Strategies for BRAF Mutation-Positive Disease 288
8.5.3 Strategies for RAS-Mutation Positive Disease 293
8.5.4 Strategies to Overcome EGFR-Acquired Resistance 297
8.5.5 Immune Checkpoint Inhibitors Combinations 300
8.5.6 Other Strategies 304
8.5.7 Liver Directed Therapies 308
8.6 Biosimilars 311
8.6.1 Bevacizumab Biosimilars 314
8.6.2 Cetuximab Biosimilars 316
9 Current and Future Players 317
9.1 Overview 317
9.2 Trends in Corporate Strategy 321
9.3 Company Profiles 322
9.3.1 Amgen 322
9.3.2 Bayer 325
9.3.3 Eli Lilly and Company 328
9.3.4 Merck KGaA 331
9.3.5 Merck & Co. 333
9.3.6 Roche/Genentech 335
9.3.7 Taiho Pharmaceutical 339
10 Market Outlook 343
10.1 Global Markets 343
10.1.1 Forecast 343
10.1.2 Drivers and Barriers - Global Issues 346
10.2 United States 349
10.2.1 Forecast 349
10.2.2 Key Events 353
10.2.3 Drivers and Barriers 353
10.3 5 EU 356
10.3.1 Forecast 356
10.3.2 Key Events 359
10.3.3 Drivers and Barriers 359
10.4 Japan 362
10.4.1 Forecast 362
10.4.2 Key Events 365
10.4.3 Drivers and Barriers 365
10.5 China 368
10.5.1 Forecast 368
10.5.2 Key Events 371
10.5.3 Drivers and Barriers 371
11 Appendix 376
11.1 Bibliography 376
11.2 Abbreviations 431
11.3 Methodology 439
11.4 Forecasting Methodology 439
11.4.1 Diagnosed CRC Patients 440
11.4.2 Percent Drug-Treated Patients 441
11.4.3 Drugs Included in Each Therapeutic Class 441
11.4.4 Launch and Patent Expiry Dates 442
11.4.5 General Pricing Assumptions 443
11.4.6 Individual Drug Assumptions 445
11.4.7 Generic Erosion 453
11.4.8 Pricing of Pipeline Agents 454
11.5 Primary Research - KOLs Interviewed for this Report 456
11.6 Primary Research - Prescriber Survey 459
11.7 About the Authors 459
11.7.1 Analyst 459
11.7.2 Reviewers 460
11.7.3 Therapy Area Director 460
11.7.4 Epidemiologist 461
11.7.5 Reviewers 461
11.7.6 Global Head of Healthcare 463
11.8 About GlobalData 463
11.9 Disclaimer 464
1.1 List of Tables
Table 1: Stage Definitions for Colorectal Cancer 33
Table 2: Symptoms of CRC 34
Table 3: Prognosis for Colon and Rectal Cancer 35
Table 4: Risk Factors and Comorbidities For CRC 38
Table 5: 8MM, Five-Year Relative Survival (%) 43
Table 6: 8MM, Sources Used to Forecast the Diagnosed Incidence of CRC 44
Table 7: 8MM, Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases of CRC 45
Table 8: 8MM, Sources of CRC Cancer Stage at Diagnosis 45
Table 9: 8MM, Sources of Genetic Mutations 47
Table 10: 8MM, Diagnosed Incident Cases of CRC (N), Both Sexes, Ages ≥18 Years, 2015-2025 58
Table 11: 8MM, Age-Specific Diagnosed Incident Cases of CRC (N), Both Sexes, Row (%), 2015 59
Table 12: 8MM, Sex-Specific Diagnosed Incident Cases of CRC (N), Ages ≥18 Years, Row (%), 2015 61
Table 13: 8MM, Diagnosed Incident Cases of CRC by Cancer Stage at Diagnosis (N), Ages ≥18 Years, Row (%), 2015 64
Table 14: 8MM, Diagnosed Incident Cases of CRC by Type of Genetic Mutation (N), Both Sexes, Ages ≥18 Years, 2015 65
Table 15: 8MM, Five-Year Diagnosed Prevalent Cases of CRC (N), Both Sexes, Ages ≥18 Years, 2015-2025 66
Table 16: Treatment Guidelines for CRC 77
Table 17: Most Prescribed Neoadjuvant/Adjuvant Regimens for Early-Stage Colon and Rectal Cancer in the 8MM, 2016 78
Table 18: Most Prescribed Targeted Therapies for mCRC, by Segment in the 8MM, 2016 79
Table 19: Country Profile - US 97
Table 20: Country Profile - France 102
Table 21: Country Profile - Germany 106
Table 22: Country Profile - Italy 110
Table 23: Country Profile - Spain 114
Table 24: Country Profile - UK 118
Table 25: Country Profile - Japan 122
Table 26: Country Profile - China 127
Table 27: Leading Treatments for CRC, 2016 132
Table 28: Product Profile - Avastin 135
Table 29: Summary of the Results from the AVF2107 Trial of Avastin Plus IFL 139
Table 30: Summary of the Results from the CALGB 80405 and FIRE-3 Trials of Avastin/Erbitux plus Chemotherapy 141
Table 31: Summary of the Results of the ML18147 Study 142
Table 32: Summary of the Results from the E3200 Trial of Avastin Plus FOLFOX 142
Table 33: Summary of AEs from the AVF21070 trial of Avastin 144
Table 34: Avastin SWOT Analysis, 2016 145
Table 35: Product Profile - Zaltrap 147
Table 36: Summary of the Results from the VELOUR Study 150
Table 37: Summary of Frequent Grade 3 and 4 AEs from the VELOUR trial of Zaltrap 151
Table 38: Zaltrap SWOT Analysis, 2016 152
Table 39: Product Profile - Cyramza 153
Table 40: Summary of the Phase III RAISE Trial of Cyramza 155
Table 41: Summary of Frequent Grade 3 and 4 AEs in a Phase III Trial for Cyramza 156
Table 42: Cyramza SWOT Analysis, 2016 157
Table 43: Product Profile - Erbitux 160
Table 44: Summary of the Result of the CRYSTAL Study 163
Table 45: Summary of the Results of the CRYSTAL Study - BRAF Mutation 164
Table 46: Retrospective Analysis of CRYSTAL and FIRE-3 Studies of Erbitux 165
Table 47: Summary of Frequent AEs from the CRYSTAL Trial of Erbitux 166
Table 48: Erbitux SWOT Analysis, 2016 167
Table 49: Product Profile - Vectibix 168
Table 50: Summary of the Results from the PRIME Trial of Vectibix 172
Table 51: Summary of the Results from the PEAK Study of Vectibix 173
Table 52: Summary of the Results from the Phase III Study of Vectibix as Monotherapy 174
Table 53: Summary of the Results from the ASPECCT Study of Vectibix 174
Table 54: Incidence of Grade 3-4 AEs of the PRIME Trial of Vectibix 175
Table 55: Vectibix SWOT Analysis, 2016 176
Table 56: Product Profile - Stivarga 177
Table 57: Summary of the Results from the CORRECT Study of Stivarga 181
Table 58: Summary of Frequent Grade 3 and 4 AEs from the CORRECT Trial of Stivarga 183
Table 59: Stivarga SWOT Analysis, 2016 184
Table 60: Product Profile - Lonsurf 186
Table 61: Summary of the Phase III RECOURSE Trial of Lonsurf 190
Table 62: Summary of the AEs in the Phase III Trial of Lonsurf 192
Table 63: Lonsurf SWOT Analysis, 2016 193
Table 64: Product Profile - TS-1 194
Table 65: Summary of a Phase III trial of TS-1 196
Table 66 Summary of Most Common AEs in a Phase III Trial of TS-1 197
Table 67: TS-1 SWOT Analysis, 2016 198
Table 68: Unmet Needs and Opportunities in CRC 201
Table 69: Product Profile - Lefitolimod 222
Table 70: Summary of the IMPACT Trial of Lefitolimod 225
Table 71: Summary of the Most Common AEs Reported in the IMPACT Trial of Lefitolimod 226
Table 72: Lefitolimod SWOT Analysis, 2016 228
Table 73: Product Profile - Keytruda 229
Table 74 Summary of the Results of the Phase II Trial of Keytruda 233
Table 75: Summary of Frequent AEs in the Phase II Trial of Keytruda 234
Table 76: Keytruda SWOT analysis, 2016 236
Table 77: Product Profile - Tecentriq 237
Table 78: Summary of the Phase Ib Trial of Tecentriq 241
Table 79: Summary of Frequent AEs in the Phase Ib Trial of Tecentriq 242
Table 80: Tecentriq SWOT analysis, 2016 244
Table 81: Product Profile - Encorafenib +Binimetinib 245
Table 82: Summary of the Results from the Phase II Trial of Encorafenib 249
Table 83: Summary of Frequent AEs in the Phase II Trial of Encorafenib 251
Table 84: Encorafenib + binimetinib - SWOT Table, 2016 253
Table 85: Product Profile - Napabucasin 254
Table 86: Summary of the Result from the Phase Ib Trial of Napabucasin 257
Table 87: Summary of the Result from the Phase II Trial Investigating Napabucasin + Vectibix 258
Table 88: Napabucasin, SWOT Analysis, 2016 260
Table 89: Product Profile - Vargatef 261
Table 90: Summary of the Result of the Phase III LUME Colon-1 Trial of Vargatef 264
Table 91: Vargatef SWOT Analysis, 2016 265
Table 92: Product Profile - Masitinib 266
Table 93: Summary of the Results of the Phase II Trial of Masitinib 269
Table 94: Masitinib SWOT Analysis, 2016 271
Table 95: Product Profile - Fruquintinib 272
Table 96: Summary of the Results of the Phase II Trial of Fruquintinib 274
Table 97: Summary of Frequent AEs in the Phase II trial of Fruquintinib 275
Table 98: Fruquintinib SWOT Analysis, 2016 277
Table 99: Product Profile - Famitinib 278
Table 100: Summary of the Results of the Phase II Trial of Famitinib 280
Table 101: Summary of Frequent AEs in a Phase II trial of Famitinib 280
Table 102: Famitinib SWOT Analysis, 2016 282
Table 103: Product Profile - Donafenib 283
Table 104: Donafenib SWOT Analysis, 2016 285
Table 105: Promising strategies to overcome VEGF resistance 286
Table 106: Early-stage Strategies for BRAF Mutation-Positive CRC 290
Table 107: Early-stage Strategies for KRAS Mutation-Positive CRC 295
Table 108: Early-Stage Strategies for EGFR Acquired Resistance 298
Table 109: Anti-PD1 and Anti-PDL1 Drugs in Early-Stage Development for CRC 302
Table 110: CAR-T Cell Therapies Under Development 305
Table 111: Vaccines in Development in CRC 307
Table 112: Radioembolization Tecnhiquese Evaluated for the Treatment of Colorectal Cancer Liver Metastasis 309
Table 113: List of Bevacizumab Biosimilars in Phase III Development 314
Table 114: Key Companies in the CRC Market in the 8MM, 2015-2025 319
Table 115: Amgen’s CRC Portfolio Assessment, 2016 324
Table 116: Bayer’s CRC Portfolio Assessment, 2016 327
Table 117: Eli Lilly’s CRC Portfolio Assessment, 2016 330
Table 118: Merck KGaA’s CRC Portfolio Assessment, 2016 332
Table 119: Merck & Co.’s CRC Portfolio Assessment, 2016 335
Table 120: Roche’s CRC Portfolio Assessment, 2016 338
Table 121: Taiho’s CRC Portfolio Assessment, 2016 341
Table 122: CRC Market Drivers and Barriers, 2016 346
Table 123: Key Events Impacting Sales for CRC in the US, 2015-2025 353
Table 124: US CRC Market Drivers and Barriers, 2016 353
Table 125: Key Events Impacting Sales for CRC in the 5EU, 2015-2025 359
Table 126: 5EU CRC Market Drivers and Barriers, 2016 359
Table 127: Key Events Impacting Sales for CRC in Japan, 2015-2025 365
Table 128: Japan CRC Market - Drivers and Barriers, 2016 365
Table 129: Key Events Impacting Sales for CRC in China, 2015-2025 371
Table 130: China CRC Market - Drivers and Barriers, 2016 371
Table 131: Key Historical and Projected Launch Dates for Colorectal Cancer 442
Table 132: Key Historical and Projected Patent Expiry Dates for Colorectal Cancer 443
Table 133 Average Body Weight and Surface Area Across the 8MM 445
Table 134: Treatment Duration in Colorectal Cancer 445
Table 135: Average Cost of Therapy of Avastin in the 8MM 446
Table 136: Average Cost per Cycle of Chemotherapy Regimens in the 8MM 448
Table 137: Average Cost of Therapy of Cyramza in the 8MM (excluding urban China) 449
Table 138: Average Cost of Therapy of Erbitux in the 8MM 450
Table 139: Average Cost of Therapy of Lonsurf in the 8MM 451
Table 140: Average Cost of Therapy of Stivarga in the 8MM 452
Table 141: Average Cost of Therapy of Vectibix in the 8MM 452
Table 142: Average Cost of Therapy of Zaltrap in the US and 5EU 453
Table 143: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 459
1.2 List of Figures
Figure 1: 8MM, Age-Adjusted Incidence Rate for CRC (Cases per 100,000 Population), Men, Ages ≥15 Years, 1998-2007 41
Figure 2: 8MM, Age-Adjusted Incidence Rate for CRC (Cases per 100,000 Population), Women, Ages ≥15 Years, 1998-2007 42
Figure 3: 8MM, Diagnosed Incident Cases of CRC (N), Both Sexes, Ages ≥18 Years, 2015-2025 58
Figure 4: 8MM, Age-Specific Diagnosed Incident Cases of CRC (N), Both Sexes, Ages ≥18 Years, 2015 60
Figure 5: 8MM, Sex-Specific Diagnosed Incident Cases of CRC (N), Ages ≥18 Years, 2015 62
Figure 6: 8MM, Age-Standardized Incidence of CRC (Cases per 100,000 Population), Ages ≥18 Years, by Sex, 2015. 63
Figure 7: 8MM, Five-Year Diagnosed Prevalent Cases of CRC (N), Both Sexes, Ages ≥18 Years, 2015-2025 66
Figure 8: Treatment Flowchart for Regional or Locoregional CRC 84
Figure 9: Treatment Flowchart for mCRC 88
Figure 10: The Zurich Treatment Algorithm 92
Figure 11: Avastin’s Development in CRC 138
Figure 12: Cyramza’s Development in CRC 155
Figure 13: Erbitux’s Development in CRC 162
Figure 14: Vectibix Development in CRC 171
Figure 15: Stivarga’s Development in CRC 181
Figure 16: Lonsurf’s Development in CRC 189
Figure 17: TS-1 Development in CRC 196
Figure 18: CRC - Phase III Pipeline, 2016 220
Figure 19: Competitive Assessment of Late-Stage Pipeline Agents in CRC, 2015-2025 221
Figure 20: Lefitolimod’s Clinical Development in CRC 224
Figure 21: Clinical and Commercial Positioning of Lefitolimod 227
Figure 22: Keytruda’s Clinical Development in CRC 232
Figure 23: Clinical and Commercial Positioning of Keytruda 235
Figure 24: Tecentriq’s Clinical Development in CRC 240
Figure 25: Clinical and Commercial Positioning of Tecentriq 243
Figure 26: Encorafenib’s Clinical Development in CRC 249
Figure 27: Potential Clinical and Commercial Positioning for Encorafenib + BInimetinib 252
Figure 28: Napabucasin’s Clinical Development in CRC 257
Figure 29: Clinical and Commercial Positioning of Napabucasin 259
Figure 30: Vargatef’s Clinical Development in CRC 263
Figure 31: Clinical and Commercial Positioning of Vargatef 265
Figure 32:Masitinib’s Clinical Development in CRC 268
Figure 33: Clinical and Commercial Positioning of Masitinib 270
Figure 34: Fruquintinib’s Clinical Development in CRC 274
Figure 35: Clinical and Commercial Positioning of Fruquintinib 276
Figure 36: Famitinib’s Clinical Development in CRC 279
Figure 37: Clinical and Commercial Positioning of Famitinib 281
Figure 38: Donafenib’s Clinical Development in CRC 284
Figure 39: Clinical and Commercial Positioning of Donafenib 284
Figure 40: Clinical Development of Bevacizumab Biosimilars 315
Figure 41: Global Sales of Branded Products for CRC by Company, 2015-2025 320
Figure 42: Company Portfolio Gap Analysis in CRC, 2015-2025 321
Figure 43: Amgen SWOT Analysis in CRC, 2016 325
Figure 44: Bayer SWOT Analysis in CRC, 2016 327
Figure 45: Eli Lilly SWOT Analysis in CRC, 2016 330
Figure 46: Merck KGaA SWOT Analysis in CRC, 2016 333
Figure 47: Merck & Co. SWOT Analysis in CRC, 2016 335
Figure 48: Roche SWOT Analysis in CRC, 2016 339
Figure 49: Taiho SWOT Analysis in CRC, 2016 342
Figure 50: Global Sales for CRC by Region, 2015-2025 345
Figure 51: Global Sales for CRC by Drug Class, 2015-2025 346
Figure 52: Sales for CRC in the US, by Drug Class, 2015-2025 352
Figure 53: Sales for CRC in the 5EU, by Drug Class, 2015-2025 358
Figure 54: Sales for CRC in Japan, by Drug Class, 2015-2025 364
Figure 55: Sales for CRC in China by Drug Class, 2015-2025 370
